Previous 10 | Next 10 |
Clinical-stage biotech biopharmaceutical company Legend Biotech Corporation ( NASDAQ: LEGN ) announced on Thursday that the company ended its Phase 1 Clinical Trial for CAR-T candidate LB1901 involving adults with relapsed or refractory T-cell lymphoma. Legend ( LEGN )...
The eleven sectors of the S&P 500 were 16.4% lower for Q2 2022, with SPDR S&P 500 Trust ETF closed more than 16% lower . The top five gainers in the health care sector (stocks with a market cap of over $2B) were: Turning Point Therapeutics ( TPTX ) +179.1...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Clinical-stage biotech Graphite Bio (NASDAQ:GRPH) traded sharply higher on Friday after BMO Capital Markets initiated its coverage with an Outperform rating and a $12 per share target implying a premium of ~461% to the last close. The analyst Kostas Biliouris highlights the company’s g...
The shares of Legend Biotech (LEGN) and Verve Therapeutics (NASDAQ:VERV) are on the rise in the morning hours Friday after BMO Capital Markets initiated their coverage, categorizing the biotech firms as its top picks. As reasons for the classification, the analyst Kostas Biliouris highlights ...
28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meeting Overall response rate remains at 98 percent after more than two years, with median progression-free and ...
Legend Biotech (NASDAQ:LEGN) on Friday said the U.S. Food and Drug Administration had cleared its investigational new drug application to evaluate its CAR-T cell therapy LB1908 in a phase 1 trial in the U.S. LB1908 is a CAR-T cell therapy that selectively targets the Claudin 18.2 protein whic...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational n...
The U.S. FDA has lifted a clinical hold on a phase 1 trial of Legend Biotech's (NASDAQ:LEGN) LB1901, a CAR-T candidate for relapsed or refractory T-cell lymphoma. In its Q1 2022 earnings results, the biotech said the lift occurred on May 25. The hold was initially placed in February afte...
Legend Biotech press release (NASDAQ:LEGN): Q1 GAAP EPS of -$0.13. Revenue of $40.83M (+198.5% Y/Y). “The year began with an exciting start as we received the company’s first-ever U.S. FDA approval for CARVYKTI™,” said Ying Huang, Ph.D., CEO of Legen...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...